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Introduction {#cam4594-sec-0001}
============

Androgen deprivation treatment (ADT) has been the gold standard in treatment of prostate cancer with distant metastases for more than half a century [1](#cam4594-bib-0001){ref-type="ref"}, [2](#cam4594-bib-0002){ref-type="ref"}, [3](#cam4594-bib-0003){ref-type="ref"}. However, the response to ADT varies, and approximately 15% of men with metastatic disease primarily fail to respond to ADT [1](#cam4594-bib-0001){ref-type="ref"}, [4](#cam4594-bib-0004){ref-type="ref"}, [5](#cam4594-bib-0005){ref-type="ref"}, [6](#cam4594-bib-0006){ref-type="ref"}, [7](#cam4594-bib-0007){ref-type="ref"}, [8](#cam4594-bib-0008){ref-type="ref"}, [9](#cam4594-bib-0009){ref-type="ref"}, [10](#cam4594-bib-0010){ref-type="ref"}, [11](#cam4594-bib-0011){ref-type="ref"}, [12](#cam4594-bib-0012){ref-type="ref"}. Not only did Huggins and coworkers describe the significant improvement in the clinical condition of patients with metastatic prostate cancer treated with ADT, they also defined a new disease state of early ADT‐refractory prostate cancer, that is, early ADT failure [1](#cam4594-bib-0001){ref-type="ref"}. In their series of 21 consecutive patients "a noticeable improvement occurred in the clinical status for all but three patients."

In the vast majority of cases ADT leads to symptomatic relief, regression of metastases, and a fall in serum Prostate Specific Antigen (PSA). With optimal management, median survival time for men with metastatic disease is now 30--49 months [13](#cam4594-bib-0013){ref-type="ref"} and survival longer than 10 years occasionally occurs [14](#cam4594-bib-0014){ref-type="ref"}. With time, however, the disease ceases to respond to hormone manipulation, becomes castration resistant, and the patient eventually dies of cancer progression unless death due to an unrelated cause intervenes. The secondary ADT failure (castration resistance) of metastatic prostate cancer after long‐term ADT has received increasing attention over the last two decades. The reason for this is that new hormonal and chemotherapeutic methods have been introduced and the mechanisms behind the development of castration resistance have been extensively explored [11](#cam4594-bib-0011){ref-type="ref"}, [15](#cam4594-bib-0015){ref-type="ref"}, [16](#cam4594-bib-0016){ref-type="ref"}, [17](#cam4594-bib-0017){ref-type="ref"}. As yet there are no predictors of early ADT failure. Results of previous studies on clinical associations between androgen receptors and treatment response in prostate cancer have been questioned [4](#cam4594-bib-0004){ref-type="ref"}, [18](#cam4594-bib-0018){ref-type="ref"}. Theories of the present time include both androgen receptor dependent and androgen receptor independent mechanisms [19](#cam4594-bib-0019){ref-type="ref"}, [20](#cam4594-bib-0020){ref-type="ref"}. Biochemical and histochemical assays have failed to predict primary response to ADT [21](#cam4594-bib-0021){ref-type="ref"}, [22](#cam4594-bib-0022){ref-type="ref"}, [23](#cam4594-bib-0023){ref-type="ref"}. Much focus has been placed on serum testosterone and other sex hormone levels and their relation to prostate cancer; but the results have been inconclusive [24](#cam4594-bib-0024){ref-type="ref"}, [25](#cam4594-bib-0025){ref-type="ref"}, [26](#cam4594-bib-0026){ref-type="ref"}. Although certain gene alterations or signatures have prognostic significance in primary prostate cancer, the clinical impact of primary prostate cancer genomic events has yet to be seen [17](#cam4594-bib-0017){ref-type="ref"}, [27](#cam4594-bib-0027){ref-type="ref"}, [28](#cam4594-bib-0028){ref-type="ref"}, [29](#cam4594-bib-0029){ref-type="ref"}. Models using molecular profiles of the primary tumor were not superior to models using clinical variables only to predict disease progress [30](#cam4594-bib-0030){ref-type="ref"}. The aim of this study was to analyze early ADT failure and to define clinical predictors associated with short survival due to early ADT failure in prostate cancer patients with bone metastases.

The 915 patients in this study were taken from a prospective noninferiority clinical trial (No. 5) conducted by the Scandinavian Prostate Cancer Group.

Methods and Patients {#cam4594-sec-0002}
====================

Clinical characteristics {#cam4594-sec-0003}
------------------------

This study was based on a Phase III study on 915 men with hormone‐naive metastatic prostate cancer from 61 centers in Denmark, Finland, Iceland, Norway and Sweden. Patients were included between December 1992 and June 1997 [31](#cam4594-bib-0031){ref-type="ref"}, [32](#cam4594-bib-0032){ref-type="ref"}. To be eligible, patients were required to have skeletal metastases (M1) and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0--2; 0 = denotes fully active; 1 = restricted in strenuous activity but ambulatory; 2 = ambulatory and capable of self‐care but unable to work). The primary objective of the trial was to determine whether or not overall‐ and cause‐specific survival following high‐dose parenteral estrogen therapy was inferior to that following Total Androgen Blockade (TAB). The extent of the primary tumor was determined using digital rectal examination according to the TNM classification from 1987 [33](#cam4594-bib-0033){ref-type="ref"} and cytological or histological specimens graded according to the World Health Organization (WHO) system [34](#cam4594-bib-0034){ref-type="ref"}. PSA, Alkaline Phosphatase (ALP), testosterone and hemoglobin levels were determined by routine laboratory testing before the start of treatment. Serum estrogen and Sex Hormone‐Binding Globulin (SHBG) levels were optional.

Skeletal involvement was assessed using bone scans supplemented by X‐ray when necessary. The extent of skeletal metastases was calculated according to a modified Soloway score: 1 = the total area of hot spots less than three lumbar vertebral bodies; 2 = total area of hot spots larger than of score 1, but \<75% of the total scan; and 3 ≥ 75% of the total scan or super scan [35](#cam4594-bib-0035){ref-type="ref"}. The presence of nonregional lymph nodes and soft tissue metastases was not investigated by CT or MRT scan.

Treatment {#cam4594-sec-0004}
---------

The patients were randomized to TAB or treatment with polyestradiol phosphate (240 mg) given by intramuscular injection every 2 weeks for 8 weeks and monthly thereafter. TAB consisted of orchiectomy or medical castration with the LHRH agonist triptorelin, according to clinician and patient preference, combined with 250 mg flutamide taken orally three times daily. In the TAB group, 298 patients chose orchiectomy, and 159 men received medical castration by monthly injection of the LHRH agonist triptorelin. No significant differences in survival between the two treatment groups were seen [31](#cam4594-bib-0031){ref-type="ref"}.

Ethics {#cam4594-sec-0005}
------

The study was performed in accordance with the recommendations of the Helsinki Declaration and approved by the ethics committees of all centers partaking in the study. Patients were given verbal and written information, and gave their informed consent to be included in the study.

Statistical methods {#cam4594-sec-0006}
-------------------

In this study, early ADT failure was defined as a patient dying of prostate cancer within 12 months after start of treatment. The cohort of 915 patients was then divided into two groups: cases that were defined as having an early ADT failure (*n* = 94) and those in the remaining cohort (*n* = 821) (Fig. [1](#cam4594-fig-0001){ref-type="fig"}).

![Flowchart showing study group assembly and follow‐up of the Scandinavian Prostate Cancer Group (SPCG) No. 5 Trial on androgen deprivation treatment (ADT) in men with prostate cancer and bone metastases. Early ADT failure was defined as disease‐specific death within 12 months after start of treatment.](CAM4-5-407-g001){#cam4594-fig-0001}

Differences in the characteristics of the early ADT failure group and those in the remaining cohort were tested using the chi‐squared test based on age at enrolment, cancer‐related pain, treatment, cardiovascular comorbidity, ECOG PS, analgesic consumption, grade of malignancy, T category, PSA level, Soloway score, hemoglobin, SHBG, estradiol, and testosterone levels. A univariate logistic regression model with odds ratio (OR) and corresponding 95% confidence interval (CI) was used to estimate the likelihood of early ADT failure for each variable. In order to identify independent predictors of early ADT failure, a multivariate logistic regression model was then constructed using all variables that were statistically significant in the univariate analyses. We applied three different criteria for early ADT failure. In a first scenario analysis, we defined primary ADT as death of any cause within 12 months (*N* = 137). In the second, we applied the same definition, but excluded 44 men who died of other causes them prostate cancer within 12 months from the study group, leaving 871 men for analyses. In the final scenario, we included all men who died of prostate cancer, regardless of time since randomization (*N* = 661 patients) but excluded those who died of other causes. For each scenario, we repeated all the univariate and multivariate logistic regression analyses. The study group assembly of the first scenario is shown in Figure [1](#cam4594-fig-0001){ref-type="fig"}. All *P*‐values were two‐sided and statistical significance was considered at *P* \< 0.05. All analyses were performed using the R version 3.1.1 (Vienna, Austria).

Results {#cam4594-sec-0007}
=======

Baseline demographic and clinical characteristics for the 915 patients enrolled in the study by the early ADT failure group and the remaining cohort are presented in Table [1](#cam4594-tbl-0001){ref-type="table-wrap"}.

###### 

Demographic and clinical characteristics by the primary androgen deprivation treatment ADT failure group and the remaining cohort

                               Primary ADT failure   Remaining cohort   *P*‐value   Total                           
  ---------------------------- --------------------- ------------------ ----------- ------------- --------- ------- -------------
  All cases                    94                    100.0              821         100.0         --        915     100.0
  Age, years                                                                                                        
  \<65                         10                    10.6               123         15.0                    133     14.5
  65--74                       41                    43.6               393         47.9                    434     47.4
  ≥75                          43                    45.7               305         37.1          0.217     348     38.0
  Initial treatment                                                                                                 
  Polyestradiol phosphate      44                    46.8               414         50.4                    458     50.1
  TAB                          50                    53.2               407         49.6          0,579     457     49.9
  Cardiovascular comorbidity                                                                                        
  None                         80                    86.0               731         90.0                    811     89.6
  Present                      13                    14.0               81          10.0          0.354     94      10.4
  Missing                      1                     --                 9           --                      10      --
  Cancer‐related pain                                                                                               
  No pain                      21                    22.3               356         43.6                    377     41.4
  Pain                         73                    77.7               460         56.4          \<0.001   533     58.6
  Missing                      --                    --                 5           --                      5       --
  ECOG performance status                                                                                           
  0                            16                    17.0               389         47.7                    405     44.5
  1                            50                    53.2               305         37.4                    355     39.0
  2--3                         28                    29.8               122         15.0          \<0.001   150     16.5
  Missing                      --                    --                 5           --                      5       --
  Analgesic consumption                                                                                             
  Negligible                   21                    22.3               414         50.7                    435     47.8
  ≥1                           73                    77.7               402         49.3          \<0.001   475     52.2
  Missing                      --                    --                 5           --                      5       --
  Grade of malignancy                                                                                               
  WHO 1                        12                    13.3               124         15.5                    136     15.3
  WHO 2                        34                    37.8               380         47.5                    414     46.5
  WHO 3                        44                    48.9               296         37.0          0.086     340     38.2
  Missing                      4                     --                 21          --                      25      --
  T‐category                                                                                                        
  T0--T2                       12                    13.0               177         21.9                    189     21.0
  T3--T4                       80                    87.0               633         78.1          0.067     713     79.0
  Missing                      2                     --                 11          --                      13      --
  PSA, *μ*g/L                                                                                                       
  PSA \<100                    24                    25.5               223         27.3                    247     27.1
  PSA 100--500                 39                    41.5               353         43.3                    392     43.1
  PSA \>500                    31                    33.0               240         29.4          0.770     271     29.8
  Missing                      --                    --                 5           --                      5       --
  Soloway score                                                                                                     
  1                            14                    15.1               305         37.8                    319     35.4
  2--3                         79                    84.9               502         62.2          \<0.001   581     64.6
  Missing                      1                     --                 14          --                      15      --
  Hemoglobin, g/L                                                                                                   
  Median, q1--q3               108.5                 11.3--129.0        125.0       11.6--141.0   0.004     124.0   11.6--140.0
  Missing                      0                     --                 12          --                      12      --
  SHBG                                                                                                              
  Median, q1--q3               47.5                  39.8--53.3         39.5        28.0--57.8    0.164     42.0    29.3--57.0
  Missing                      78                    --                 711         --                      789     --
  Estradiol                                                                                                         
  Median, q1--q3               64.0                  0.1--82.0          65.0        0.2--98.0     0.366     64.5    0.1--96.0
  Missing                      79                    --                 712         --                      791     --
  Testosterone                                                                                                      
  Median, q1--q3               12.0                  8.3--16.6          13.2        10.0--17.4    0.042     13.0    9.8--17.2
  Missing                      11                    --                 79          --                      90      --
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A total of 94 of 915 (10.4%) patients died of progressive metastatic prostate cancer within 12 months after start of ADT and fulfilled the criteria for early ADT failure. The early ADT failure group had a statistically significant higher burden of cancer‐related pain, a poorer PS, analgesic consumption, and a higher Soloway score compared to the remaining cohort. There were also statistically significant differences with regards to level of hemoglobin and testosterone levels at the time of enrolment between the two groups. Not significantly factors related to early ADT failure were age, treatment, cardiovascular comorbidity, T‐category, grade of malignancy, serum estrogen level, and SHBG at enrolment (Table [1](#cam4594-tbl-0001){ref-type="table-wrap"}).

Factors prognostically associated with early ADT failure were defined using univariate and multivariate logistic regression analyses (Table [2](#cam4594-tbl-0002){ref-type="table-wrap"}). Factors significantly associated with early ADT failure in the univariate analyses were as follows: cancer‐related pain, a poor ECOG PS, an analgesic consumption, high Soloway score, and a low level of hemoglobin at enrolment. In the multivariate logistic regression analyses, a poor ECOG PS, analgesic consumption, a high Soloway score, and low levels of hemoglobin were all independent predictors of early ADT failure. Patients with an ECOG PS of 1 or higher, for example, had a threefold likelihood of early ADT failure compared to patients with PS of 0 (Table [2](#cam4594-tbl-0002){ref-type="table-wrap"}). The results of the 3 scenario analyses did not alter from the base case analyses (the 94 patients who died of progressive metastatic prostate cancer within 12 months), where a poor ECOG PS, analgesic consumption, a high Soloway score, and low levels of hemoglobin were all independent predictors of early ADT failure (Data not shown).

###### 

Univariate and multivariate logistic regression for primary ADT failure

                               Univariate   Multivariate          
  ---------------------------- ------------ -------------- ------ ------------
  Age, years                                                      
  \<65                         1.00         Ref.           --     --
  65--74                       1.28         0.65--2.78     --     --
  ≥75                          1.73         0.88--3.75     --     --
  Initial treatment                                               
  Polyestradiol phosphate      1.00         Ref.           --     --
  TAB                          1,16         0.75--1.78     --     --
  Cardiovascular comorbidity                                      
  None                         1.00         Ref.           --     --
  Present                      1,47         0.75--2.67     --     --
  Cancer‐related pain                                             
  No pain                      1.00         Ref.           1.00   Ref.
  Pain                         2.69         1.65--4.56     0.53   0.22--1.27
  ECOG Performance status                                         
  0                            1.00         Ref.           1.00   Ref.
  1                            3.99         2.28--7.35     3.09   1.65--6.09
  2--3                         5.58         2.96--10.88    3.47   1.67--7.44
  Analgesic consumption                                           
  Negligible                   1.00         Ref.           1.00   Ref.
  ≥1                           3.58         2.20--6.06     2.92   1.25--7.22
  Grade of malignancy                                             
  WHO 1                        1.00         Ref.           --     --
  WHO 2                        0.92         0.48--1.91     --     --
  WHO 3                        1.54         0.81--3.13     --     --
  T‐category                                                      
  T0--T2                       1.00         Ref.           1.00   Ref.
  T3--T4                       1.86         1.03--3.67     1.80   0.95--3.73
  PSA, *μ*g/L                                                     
  PSA \<100                    1.00         Ref.           --     --
  PSA 100--500                 1.03         0.61--1.77     --     --
  PSA \>500                    1.20         0.69--2.13     --     --
  Soloway score                                                   
  1                            1.00         Ref.           1.00   Ref.
  2--3                         3.43         1.97--6.41     2.22   1.24--4.25
  Hemoglobin, g/L                                                 
  High                         1.00         Ref.           1.00   Ref.
  Low                          2.11         1.35--3.35     1.65   1.03--2.69
  SHBG                                                            
  Low                          1.00         Ref.           --     --
  High                         1.43         0.50--4.27     --     --
  Estradiol                                                       
  Low                          1.00         Ref.           --     --
  High                         0.86         0.28--2.55     --     --
  Testosterone                                                    
  Low                          1.00         Ref.           --     --
  High                         0.72         0.45--1.13     --     --
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Discussion {#cam4594-sec-0008}
==========

One in ten men with metastatic prostate cancer primarily fails to respond to ADT. In this study we defined a sample of men with prostate cancer and bone metastases as being nonresponders to ADT based on the fact that they died of the disease within 12 months after start of ADT. Nonresponders had a significantly poorer ECOG PS, analgesic consumption, lower hemoglobin, and greater extent of bone metastases. Although it was already realized at the beginning of the ADT‐era that there was a subgroup of prostate cancer patients, who do not primarily responded to ADT, few studies have been undertaken to elucidate this phenomenon even though it continues to be mentioned in the uro‐oncologic literature [1](#cam4594-bib-0001){ref-type="ref"}, [4](#cam4594-bib-0004){ref-type="ref"}, [5](#cam4594-bib-0005){ref-type="ref"}, [6](#cam4594-bib-0006){ref-type="ref"}, [7](#cam4594-bib-0007){ref-type="ref"}, [10](#cam4594-bib-0010){ref-type="ref"}, [11](#cam4594-bib-0011){ref-type="ref"}, [36](#cam4594-bib-0036){ref-type="ref"}, [37](#cam4594-bib-0037){ref-type="ref"}.

A state of castration resistance usually develops after long‐term ADT. Improving the results of metastatic castration‐resistant prostate cancer (mCRPC) treatment is currently regarded as one of the most critical goals in the management of the disease [12](#cam4594-bib-0012){ref-type="ref"}, [38](#cam4594-bib-0038){ref-type="ref"}, [39](#cam4594-bib-0039){ref-type="ref"}, [40](#cam4594-bib-0040){ref-type="ref"}. A better understanding of the mechanisms behind secondary resistance following long‐term ADT may eventually result in a better understanding of early ADT failure. However, mCRPC following long‐term ADT is probably a much more heterogeneous condition than metastatic prostate cancer primarily failing to respond to ADT [17](#cam4594-bib-0017){ref-type="ref"}.

All men who died of progressive prostate cancer within 12 months of starting ADT were included, though there was a slight bias in the criteria in that any disease‐specific death during the first 12 months was considered to be early ADT failure. There may also have been men who did not respond to ADT that died after 12 months of treatment as well. In the pre‐ADT era, prostate cancer with bone metastases had a very short survival expectation, with a nine‐month mortality rate of 66%. However, long‐term survival was sometimes seen even in the pre‐ADT era [41](#cam4594-bib-0041){ref-type="ref"}.

When the idea of ADT evolved, it was suggested that androgen regulation played a central role. When assessing early "failure cases" [42](#cam4594-bib-0042){ref-type="ref"}, it was found that those with small testes at time of castration had a poor prognosis. Later, Houghton et al. reported no influence of the pretreatment testosterone concentrations on the outcome of prostate cancer [25](#cam4594-bib-0025){ref-type="ref"}. In some studies, however, prostate cancer has been considered to be more aggressive in the presence of low testosterone levels at start of ADT [43](#cam4594-bib-0043){ref-type="ref"}, [44](#cam4594-bib-0044){ref-type="ref"}.

Medical castration achieved by administration of long‐acting LHRH agonists or estrogens has been demonstrated to be as effective as surgical castration. Although LHRH agonists formulations may differ from estrogens in their suppression of testosterone, there are no data relating these differences to cause‐specific survival. Furthermore, there is no generally accepted limit for serum testosterone after ADT. Recently a value of 0.2 ng/mL or 0.69 nmol/L was suggested, but studies comparing clinical outcome with different castration limits are lacking [45](#cam4594-bib-0045){ref-type="ref"}. Uncertainties concerning the role of circulating sex hormones, and response to ADT have prompted the need to measure intraprostatic hormone levels and to compare these with their circulating correlates [26](#cam4594-bib-0026){ref-type="ref"}, [46](#cam4594-bib-0046){ref-type="ref"}, [47](#cam4594-bib-0047){ref-type="ref"}. Residual androgens at levels sufficient to activate the androgen receptor were found in prostate tissue, despite castrate levels of serum testosterone [48](#cam4594-bib-0048){ref-type="ref"}.

The previous findings of PSA as prognostic marker for prostate cancer treatment [49](#cam4594-bib-0049){ref-type="ref"} could not be confirmed in this study. The first clinical indication that a patient responds to ADT is that the serum PSA level decreases. In 856 of the originally 915 cases, the serum PSA level had fallen 3 months after start of ADT. The observed PSA decrease in these cases was probably not only due to regression of tumor volume. At the cellular level a fall in PSA levels reflects a decrease in androgen receptor stimulation corresponding to a decreased transcription of the androgen‐responsive PSA gene and secretion of its encoded protein. The reason for the decrease in PSA may, to some extent, be due to the elimination of stimulation of PSA production by circulating androgens [50](#cam4594-bib-0050){ref-type="ref"}. We have not assessed the role of PSA kinetics, but focused on patients\' variables before treatment start. The reason was the small number of patients in the early ADT failure group. Seven of the 94 patients already died within 3 months and 44 within 9 months. A previous study found that the level of pretreatment PSA or Gleason score at diagnosis could not predict patients likely to be unresponsive to ADT [51](#cam4594-bib-0051){ref-type="ref"}. [52](#cam4594-bib-0052){ref-type="ref"}, however, demonstrated a correlation between high Gleason score and positivity for chromogranin A in prostate cancer bone metastases and with poor outcome.

Our finding that prostate cancer with more extensive bone metastases is associated with ADT failure agrees with the results of other studies [53](#cam4594-bib-0053){ref-type="ref"}. Similarly, poor PS [43](#cam4594-bib-0043){ref-type="ref"}, [54](#cam4594-bib-0054){ref-type="ref"}, [55](#cam4594-bib-0055){ref-type="ref"}, and analgesic consumption [56](#cam4594-bib-0056){ref-type="ref"}, have been shown to be predictive for short survival in some studies. Analyses within groups having pain versus no pain at entry revealed poor survival when pain initially was present [5](#cam4594-bib-0005){ref-type="ref"}.

In this study all patients had bone metastases, but the presence of distant metastases at other sites was not explored. There is some evidence from clinical trials that treatment results are not related to the site of distant metastases [57](#cam4594-bib-0057){ref-type="ref"}. Recently, however, it was shown that the pattern of spread of distant metastases affects prognosis [58](#cam4594-bib-0058){ref-type="ref"}. These data, however, require validation.

The negative influence of low hemoglobin at the start of ADT seen in this study is in accordance with previous trials [54](#cam4594-bib-0054){ref-type="ref"}, [56](#cam4594-bib-0056){ref-type="ref"}.

Conclusion {#cam4594-sec-0009}
==========

Using data from a previous randomized clinical trial, we analyzed and compared the clinical characteristics of men with prostate cancer with bone metastases receiving ADT, and who showed early treatment failure. Using multivariate analyses, poor ECOG PS, analgesic consumption, high Solowey score, and a low hemoglobin were found to be predictive of early ADT failure. Men with these characteristics should be considered for alternative treatment.
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